First gene-editing treatment injected into the blood reduces toxic protein for up to 1 year
By Jocelyn Kaiser,
Science
| 03. 01. 2022
Cas9 from CRISPR from NIH, CC BY-NC 2.0
The first team to disable a disease gene directly in a person through an infusion of the genome editor CRISPR reported yesterday that levels of the toxic protein made by the gene dropped as much as 93% for up to 1 year. The researchers hope the long-term reduction means patients in the clinical trial will soon show clear improvement in their nerve symptoms and that these benefits will persist for an extended period.
“It is quite remarkable that this first [intravenous] CRISPR-based gene-editing effort has been so successful,” says gene therapy researcher Terence Flotte of the University of Massachusetts Medical School, who was not involved with the study. “This demonstrates great potential for the power of this platform clinically.”
People who have inherited a gene mutation responsible for a condition known as transthyretin (TTR) amyloidosis can develop nerve pain, numbness, and heart failure as adults. The genetic defect results in buildup in nerves and organs of a misfolded version of TTR, a protein made by the liver. Last year, the companies...
Related Articles
GeneWatch UK has prepared a briefing on the genetic modification of nature for the International Union for Conservation of Nature (IUCN) Congress in October 2025
The upcoming Congress claims to be “where the world comes together to set priorities and drive conservation and sustainable development action.” A major concern for those on the outside is that the Congress may advance plans to develop and encourage the use of synthetic biology in nature conservation. This could at first glance sound like...
By Aaron Ginn, The Washington Post | 09.12.2025
Earlier this year, I had dinner in D.C. with Jensen Huang, the president and chief executive of Nvidia. At one point, he said something that struck me: “Why is everyone here so negative?”
He wasn’t referring to the economy...
By Roni Caryn Rabin, The New York Times | 08.25.2025
Scientists have dreamed for centuries about using animal organs to treat ailing humans. In recent years, those efforts have begun to bear fruit: Researchers have begun transplanting the hearts and kidneys of genetically modified pigs into patients, with varying degrees...
The Center for Genetics and Society is delighted to recommend the current edition of GMWatch Review – Number 589. UK-based GMWatch, a long-standing ally, was founded in 1998 by Jonathan Matthews as an independent organization seeking to counter the enormous corporate political power and propaganda of the GMO industry and its supporters. Matthews and Claire Robinson are its directors and managing editors.
CGS works to ensure that social justice, equity, human rights, and democratic governance are front...